Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From TheraVida, Inc.
Celgene reworks its collaboration with Abide, dropping its buyout option. Roivant gains Chinese rights to anti-infective lemafulin and adds a fifth candidate to Dermavant's pipeline, while pSivida acquires Icon and FDA-approved Dexycu for cataract surgery inflammation.
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type –Acquisition, Alliance, or Financing.
The news in a nutshell
TheraVida said it intends to conduct additional international clinical trials of its lead product candidate, Tolenix (THVD-201), for the treatment of overactive bladder (OAB) and urge urinary incontinence (UUI) having reported positive Phase II data for the drug.
- Specialty Pharmaceuticals